Key Points
- Harlan Robins sold 10,000 ADPT shares on Jan. 6 at an average price of $16.44 for $164,400, trimming his stake by 0.81% to 1,222,312 shares (≈$20.09M).
- Adaptive reported Q results showing revenue of $93.97M (up 102.4% YoY) and a slight EPS beat, but remains unprofitable with negative margins and a projected -0.92 EPS for the fiscal year.
- Analyst sentiment is broadly positive—consensus is a "Moderate Buy" (9 Buys, 1 Hold, 1 Sell) with an average target of $17.11 and several firms raising targets into the $20–21 range.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) insider Harlan Robins sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.44, for a total transaction of $164,400.00. Following the completion of the transaction, the insider owned 1,222,312 shares of the company's stock, valued at approximately $20,094,809.28. This trade represents a 0.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Adaptive Biotechnologies Trading Down 4.6%
Shares of ADPT opened at $15.96 on Friday. The company has a market capitalization of $2.44 billion, a PE ratio of -29.56 and a beta of 2.18. Adaptive Biotechnologies Corporation has a 12 month low of $5.97 and a 12 month high of $20.76. The stock's 50-day moving average price is $16.48 and its two-hundred day moving average price is $14.25.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.01. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The company had revenue of $93.97 million during the quarter, compared to the consensus estimate of $58.76 million. During the same period last year, the company earned ($0.22) earnings per share. The firm's revenue was up 102.4% compared to the same quarter last year. Equities research analysts predict that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.
Analyst Ratings Changes
A number of research analysts have recently issued reports on the company. JPMorgan Chase & Co. boosted their price objective on Adaptive Biotechnologies from $17.00 to $20.00 and gave the company an "overweight" rating in a research note on Thursday, November 6th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Adaptive Biotechnologies in a report on Wednesday, October 8th. Cowen restated a "buy" rating on shares of Adaptive Biotechnologies in a report on Wednesday. Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a research report on Monday, December 1st. They set an "equal weight" rating and a $21.00 price objective for the company. Finally, BTIG Research boosted their target price on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a "buy" rating in a research report on Thursday, November 6th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Adaptive Biotechnologies presently has a consensus rating of "Moderate Buy" and an average target price of $17.11.
View Our Latest Stock Analysis on Adaptive Biotechnologies
Institutional Investors Weigh In On Adaptive Biotechnologies
Several hedge funds and other institutional investors have recently modified their holdings of ADPT. Sound Income Strategies LLC acquired a new position in shares of Adaptive Biotechnologies during the third quarter worth approximately $30,000. Smartleaf Asset Management LLC increased its stake in Adaptive Biotechnologies by 593.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company's stock valued at $59,000 after purchasing an additional 3,371 shares in the last quarter. Caxton Associates LLP acquired a new position in Adaptive Biotechnologies during the first quarter worth $93,000. Teza Capital Management LLC bought a new position in shares of Adaptive Biotechnologies in the first quarter valued at $118,000. Finally, Quadrant Capital Group LLC bought a new position in shares of Adaptive Biotechnologies in the third quarter valued at $133,000. Institutional investors own 99.17% of the company's stock.
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
